. 2021 Dec 30;57(4):568–574. doi: 10.1177/00185787211066460

Table 3.

Group Comparison on Dichotomous Outcomes.

Outcome variable	Drug	N (patients)	Group comparison		Adjusted/conditional group comparison^*
Outcome variable	Drug	N (patients)	% Experiencing outcome	P ^{^}	% Experiencing outcome	Coefficient	Std. error	Odds ratio (95% CI)	P
Clinical cure	Ertapenem	55	96.4	.091	96.8	−1.823	0.896	0.16 (0.03-0.94)	.042
Clinical cure	Cefoxitin	30	83.3	.091	83.2	−1.823	0.896	0.16 (0.03-0.94)	.042
Microbiological cure	Ertapenem	16	100.0	.192	100.0	−19.130	4077.160	^$	.996
Microbiological cure	Cefoxitin	13	84.6	.192	88.6	−19.130	4077.160	^$	.996
Vasopressor use (in critically ill patients)	Ertapenem	55	12.7	.250	12.8	−1.497	1.101	0.22 (0.03-1.94)	.174
Vasopressor use (in critically ill patients)	Cefoxitin	30	3.3	.250	3.2	−1.497	1.101	0.22 (0.03-1.94)	.174
Relapse/recurrence within 30 days	Ertapenem	55	18.2	.999	18.1	−0.133	0.611	0.88 (0.26-2.90)	.828
Relapse/recurrence within 30 days	Cefoxitin	29	17.2	.999	16.2	−0.133	0.611	0.88 (0.26-2.90)	.828
Relapse/recurrence within 90 days	Ertapenem	55	34.5	.070	34.8	−1.229	0.613	0.29 (0.09-0.97)	.045
Relapse/recurrence within 90 days	Cefoxitin	29	13.8	.070	13.5	−1.229	0.613	0.29 (0.09-0.97)	.045
Mortality within 90 days	Ertapenem	55	0.0	.122	0.0	21.539	5243.711	^$	.997
Mortality within 90 days	Cefoxitin	30	6.7	.122	1.8	21.539	5243.711	^$	.997

^{^}

Calculated using Fisher’s exact test.

Adjusted/conditional group differences performed by including the Charlson Comorbidity Index as a covariate in the logistic regression model.

Unidentified due to perfect alignment in 1 or more cells.